ULBP2 and central nervous system cancer: Interestingly, IPA showed also immune-modulating properties activating NK cells-mediated recognition of glioma cells, achieved by the upregulation of ULBP2, NKG2D ligand, in TP53 wild type cells or MICA/B in p53 mutant gliomas [9].